Nuvalent To Present Updated Data From ARROS-1 Phase 1/2 Clinical Trial Of Zidesamtinib And ALKOVE-1 Phase 1/2 Clinical Trial Of NVL-655 at ESMO Congress 2024
Nuvalent To Present Updated Data From ARROS-1 Phase 1/2 Clinical Trial Of Zidesamtinib And ALKOVE-1 Phase 1/2 Clinical Trial Of NVL-655 at ESMO Congress 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.